ADTC (M) 23/04

Minutes 34 - 43

 **NHS GREATER GLASGOW AND CLYDE**

**Minutes of the Meeting of the**

 **Area Drugs and Therapeutics Committee**

**held on Monday 21 August 2023 at 2.00pm**

**via Microsoft Teams**

**PRESENT**

Dr Scott Muir (in the Chair)

|  |  |
| --- | --- |
| Dr Katie Adair | Prof Gerard McKay |
| Dr Maureen Byrne | Ms Elaine McIvor |
| Ms Yvonne Clark | Ms Mairi-Anne McLean |
| Mr Alexander Crighton | Ms Faria Qureshi |
| Ms Ysobel Gourlay | Ms Fiona Thompson |
| Dr Roger Hardman | Mrs Janice Watt |

**IN ATTENDANCE**

|  |  |  |
| --- | --- | --- |
| Dr Brian Digby |  | Consultant Anaesthesia and Intensive Care |
| Mr James Drinkell |  | Scottish Medicine Consortium |
| Ms Andrea McLean |  | Scottish Medicine Consortium |
| Ms Catherine Tait |  | Scottish Medicine Consortium |
| Ms Eloise Tulloch |  | Pharmacist  |

|  |  |  | **ACTION BY** |
| --- | --- | --- | --- |
| **34.** | **CHAIR’S STATEMENT**  |  |  |
|  |  |  |  |
|  | The Chair reminded members that papers and proceedings related to SMC advice were, in some cases, confidential, and should not be disclosed before the relevant embargo dates. Members were reminded to make relevant declarations of interest in line with Board policy. Members were advised not to speak with members of the press on ADTC business but to refer such enquiries to the Board Press Liaison Office. **NOTED**  |  |  |
|  |  |  |  |
| **35.** | **WELCOME AND APOLOGIES**  |  |  |
|  |  |  |  |
|  | The Chair welcomed those present to the August meeting of the Area Drugs and Therapeutics Committee. Apologies for absence were intimated on behalf of:* Mark Fawcett
* Audrey Thompson
* Judith Simpson
* Aileen Muir

Welcomes noted for:* Dr Katie Adair
* James Drinkell
* Catherine Tait
* Andrea McLean

**NOTED** |  |  |
|  |  |  |  |
| **36.** | **MINUTES OF PREVIOUS MEETING** |  |  |
|  |  |  |  |
|  | The Committee considered the minute of the meeting held on Monday 19 June 2023 [Paper No. ADTC (M) 23/03] and were content to accept this as an accurate record of the meeting. **APPROVED**  |  |   |
|  |  |  |  |
| **37.** | **MATTERS ARISING** |  |  |
|  |  |  |  |
|  | There were no matters arising. **NOTED**  |  |  |
|  |  |  |  |
| **38.** | **NEW MEDICINES FOR CONSIDERATION**  |  |  |
|  |  |  |  |
| **(1)** | **REPORT ON SMC PRODUCT ASSESSMENTS**  |  |  |
|  |  |  |  |
|  | Members were asked to declare any interests specific or non-specific, personal or non-personal, on any of the drugs being discussed on an individual basis. No declarations of interest were made. *See Appendix 1 for summarised decisions.* **NOTED**  |  |  |
|  |  |  |  |
| **39.** | **ADTC SUBCOMMITTEE SIX MONTHLY REPORTS**  |  |  |
|  |  |  |  |
|  | **Non-Medicine Utilisations Subcommittee** |  |  |
|  |  |  |  |
|  | Mrs Mairi-Anne McLean presented the paper ‘Non-Medicine Utilisations Subcommittee Six Month Report’ [Paper 23/24]. Mrs McLean noted there were 10 Formularies in date and valid with 2 Formularies that had been reviewed and were awaiting sign off. In regards to reporting on Formulary Compliance, Mrs McLean advised she was working with data analysts to update the reports to include all relevant areas. The Committee were content to note the update provided. **NOTED** |  |  |
|  |  |  |  |
|  **b)** | **Antimicrobial Subcommittee** |  |  |
|  |  |  |  |
|  | Mrs Ysobel Gourlay presented the paper ‘Antimicrobial Subcommittee Six Month Report’ [Paper 23/25]. Mrs Gourlay noted that although there had been an increase in Antibiotic use within Primary Care, all 3 National Targets were being met. ( Targets are related to Antibiotic use in primary care, Acute care use of IV antibiotics and Acute care use of Access antibiotics)Mrs Gourlay highlighted the Guidelines due for review at upcoming Antimicrobial Utilisation Committee. Mrs Gourlay advised there had been an increase with Pip/Taz use and a review was underway to understand the use. In response to the question regarding 4 day use of Gentamicin, Mrs Gourlay noted this was due for review at the Antimicrobial Utilisation Committee in November. In response to the question regarding use of Pip/Taz use, Mrs Gourlay advised that hospitals in GGC used more than the Scottish average but use in GGC hospitals was not as high as use in some other Scottish Hospitals. The Committee noted the update provided.**NOTED** |  |  |
|  |  |  |  |
| **40.** | **ADTC SUBCOMMITTEE UPDATES** |  |  |
|  |  |  |  |
|  **a)** | **Communications Subcommittee** |  |  |
|  |  |  |  |
|  | No update provided. **NOTED** |  |  |
|  |  |  |  |
|  **b)** | **Safer Use of Medicines** |  |  |
|  |  |  |  |
|  | No update provided. **NOTED** |  |  |
|  |  |  |  |
|  **c)** | **Patient Group Direction** |  |  |
|  |  |  |  |
|  | Due to apologises received, There was no update provided. **NOTED** |  |  |
|  |  |  |  |
|  **d)** | **Prescribing Interface** |  |  |
|  |  |  |  |
|  | No update provided. **NOTED** |  |  |
|  |  |  |  |
|  | **PROGRESS UPDATES** |  |  |
|  |  |  |  |
| **41.** | **HEPMA PROGRESS REPORT** |  |  |
|  |  |  |  |
|  | Mrs Janice Watt presented the paper ‘HEPMA Progress Report’ [Paper 23/26]. Mrs Watt advised the planned HEPMA upgrade had been put on hold due to technical issues with the new Business Continuity. Mrs Watt advised the upgrade was needed for a number of enhancements and integration of the new Pharmacy Stock Management System which was planned for the end of the year. Mrs Watt advised the new intake of Junior Doctors had been advised to use the new IDL process as first line.Mrs Watt noted the area’s piloting the Outpatient HEPMA system. The Committee noted the update provided.**NOTED**  |  |  |
|  |  |  |  |
| **42.** | **AOCB**  |  |  |
|  |  |  |  |
|  | The Chair invited members to raise any other items of business. The Chair noted a member from ADTC Committee would be required for the ADTC Collaborative. In regards to the Terms of Reference and the duration of the Chair term, The Chair advised a pragmatic approach would be taken when reviewing the Chair position and length of term. **NOTED**  |  |  |
|  |  |  |  |
| **43.** | **DATE OF NEXT SCHEDULED MEETING**  |  |  |
|  |  |  |  |
|  | Monday 9th October 2023 at 2pm via MS Teams.  |  |  |